Revolution Medicines surges 38% on pancreatic cancer breakthrough
Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer
Business
Business
IREN stock analysis amid CoreWeave, Nebius market share gains
IREN stock price has rebounded in the past few days, moving from a low of $30 on March 30 to the current $40.
Business
Petroyuan or dollar strength? Hormuz conflict sparks global currency fight
The significance of the US dollar in global trade has taken a hit over the last couple of years, but a straightforward decline
Investing
Pound weakens amid geopolitical tensions and energy price surge
The British pound declined against a broadly stronger US dollar on Monday as escalating geopolitical tensions between the United States and Iran heightened
Investing
Why does HSBC expect the dollar to weaken despite gains?
The US dollar moved higher on Monday after weekend talks between Washington and Tehran failed to produce an agreement to end the ongoing
Economy
US-Iran peace talks fail: what’s next for VanEck Semiconductor ETF (SMH)
The VanEck Semiconductor ETF (SMH) is in sharp focus on Apr. 13 after the high-stakes US-Iran peace talks collapsed, dashing hopes of a
Economy
Intel stock is in a parabolic move, and a rare pattern points to a surge to $82
Intel stock price has staged a strong comeback this year and is now hovering near its all-time high. It soared to $62.40, up
Economy
Revolution Medicines surges 38% on pancreatic cancer breakthrough
Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer
Economy
IREN stock analysis amid CoreWeave, Nebius market share gains
IREN stock price has rebounded in the past few days, moving from a low of $30 on March 30 to the current $40.
Economy
Petroyuan or dollar strength? Hormuz conflict sparks global currency fight
The significance of the US dollar in global trade has taken a hit over the last couple of years, but a straightforward decline